Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
37 hedge funds and large institutions have $1.88M invested in Galera Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 11 closing their positions.
23% more capital invested
Capital invested by funds: $1.53M → $1.88M (+$346K)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 38 → 37 (-1)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$605K |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$140K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$91.6K |
| 4 |
Renaissance Technologies
New York
|
+$48.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$94.5K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$52.9K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$27.6K |
| 4 |
HF
HRT Financial
New York
|
-$27.6K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$19.6K |
GRTX Hedge Fund Activity: Q4 2023 in Review
37 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q4 2023, worth a combined $1.88M — up 23% from $1.53M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GRTX and 10 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 3 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $605K. The largest seller was Vanguard Group, cutting an estimated $94.5K.
- 37 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q4 2023, down from 38 in Q3 2023.
- Funds reported $1.88M of Galera Therapeutics, Inc. Common Stock stock for Q4 2023, up 23% quarter-over-quarter.
- 10 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q4 2023 and 11 closed out, a net change of -1 holder.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q4 2023 was GSA Capital Partners, an estimated $605K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q4 2023 was Vanguard Group, an estimated $94.5K sold.
Based on aggregated 13F filings for Q4 2023.